Review



s63845  (TargetMol)


Bioz Manufacturer Symbol TargetMol manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    TargetMol s63845
    (A) Schematic overview of the upper mevalonate pathway illustrating statin-mediated inhibition of HMG-CoA reductase. (B) Chemical structure of pitavastatin, a potent HMG-CoA reductase inhibitor targeting mevalonate pathway. (C) Heatmap summarizing drug synergy in 3D Ewing sarcoma cultures. Combinations of pitavastatin with the BCL-2 inhibitor ABT-199 (venetoclax), BCL-xL inhibitor A1155463, or MCL-1 inhibitor <t>S63845</t> were additive in 2D cultures (NumScore = 0) but showed marked synergy in 3D spheroids across multiple concentration points. NumScore indicates the number of wells in the dose matrix where the observed effect exceeds Bliss-predicted additivity. (D) Heatmap of MaxScore values for the SK-N-MC cell line, comparing 3D and 2D cultures. Left: High MaxScores in 3D cultures indicate strong synergy across concentration points. Right: Low MaxScores in 2D cultures highlight reduced synergistic interaction. Orange boxes denote the IC₅₀ concentrations of both pitavastatin and A1155463.
    S63845, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 5 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/s63845/product/TargetMol
    Average 94 stars, based on 5 article reviews
    s63845 - by Bioz Stars, 2026-02
    94/100 stars

    Images

    1) Product Images from "Mevalonate pathway activation in Ewing sarcoma reveals a 3D-specific synergy between statins and BCL-xL inhibition"

    Article Title: Mevalonate pathway activation in Ewing sarcoma reveals a 3D-specific synergy between statins and BCL-xL inhibition

    Journal: bioRxiv

    doi: 10.1101/2025.11.20.689456

    (A) Schematic overview of the upper mevalonate pathway illustrating statin-mediated inhibition of HMG-CoA reductase. (B) Chemical structure of pitavastatin, a potent HMG-CoA reductase inhibitor targeting mevalonate pathway. (C) Heatmap summarizing drug synergy in 3D Ewing sarcoma cultures. Combinations of pitavastatin with the BCL-2 inhibitor ABT-199 (venetoclax), BCL-xL inhibitor A1155463, or MCL-1 inhibitor S63845 were additive in 2D cultures (NumScore = 0) but showed marked synergy in 3D spheroids across multiple concentration points. NumScore indicates the number of wells in the dose matrix where the observed effect exceeds Bliss-predicted additivity. (D) Heatmap of MaxScore values for the SK-N-MC cell line, comparing 3D and 2D cultures. Left: High MaxScores in 3D cultures indicate strong synergy across concentration points. Right: Low MaxScores in 2D cultures highlight reduced synergistic interaction. Orange boxes denote the IC₅₀ concentrations of both pitavastatin and A1155463.
    Figure Legend Snippet: (A) Schematic overview of the upper mevalonate pathway illustrating statin-mediated inhibition of HMG-CoA reductase. (B) Chemical structure of pitavastatin, a potent HMG-CoA reductase inhibitor targeting mevalonate pathway. (C) Heatmap summarizing drug synergy in 3D Ewing sarcoma cultures. Combinations of pitavastatin with the BCL-2 inhibitor ABT-199 (venetoclax), BCL-xL inhibitor A1155463, or MCL-1 inhibitor S63845 were additive in 2D cultures (NumScore = 0) but showed marked synergy in 3D spheroids across multiple concentration points. NumScore indicates the number of wells in the dose matrix where the observed effect exceeds Bliss-predicted additivity. (D) Heatmap of MaxScore values for the SK-N-MC cell line, comparing 3D and 2D cultures. Left: High MaxScores in 3D cultures indicate strong synergy across concentration points. Right: Low MaxScores in 2D cultures highlight reduced synergistic interaction. Orange boxes denote the IC₅₀ concentrations of both pitavastatin and A1155463.

    Techniques Used: Inhibition, Concentration Assay



    Similar Products

    s63845  (MedChemExpress)
    96
    MedChemExpress s63845
    S63845, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/s63845/product/MedChemExpress
    Average 96 stars, based on 1 article reviews
    s63845 - by Bioz Stars, 2026-02
    96/100 stars
    		  Buy from Supplier
    set concentration  (MedChemExpress)
    96
    MedChemExpress set concentration
    Set Concentration, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/set concentration/product/MedChemExpress
    Average 96 stars, based on 1 article reviews
    set concentration - by Bioz Stars, 2026-02
    96/100 stars
    		  Buy from Supplier
    s63845  (TargetMol)
    94
    TargetMol s63845
    (A) Schematic overview of the upper mevalonate pathway illustrating statin-mediated inhibition of HMG-CoA reductase. (B) Chemical structure of pitavastatin, a potent HMG-CoA reductase inhibitor targeting mevalonate pathway. (C) Heatmap summarizing drug synergy in 3D Ewing sarcoma cultures. Combinations of pitavastatin with the BCL-2 inhibitor ABT-199 (venetoclax), BCL-xL inhibitor A1155463, or MCL-1 inhibitor <t>S63845</t> were additive in 2D cultures (NumScore = 0) but showed marked synergy in 3D spheroids across multiple concentration points. NumScore indicates the number of wells in the dose matrix where the observed effect exceeds Bliss-predicted additivity. (D) Heatmap of MaxScore values for the SK-N-MC cell line, comparing 3D and 2D cultures. Left: High MaxScores in 3D cultures indicate strong synergy across concentration points. Right: Low MaxScores in 2D cultures highlight reduced synergistic interaction. Orange boxes denote the IC₅₀ concentrations of both pitavastatin and A1155463.
    S63845, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/s63845/product/TargetMol
    Average 94 stars, based on 1 article reviews
    s63845 - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Schematic overview of the upper mevalonate pathway illustrating statin-mediated inhibition of HMG-CoA reductase. (B) Chemical structure of pitavastatin, a potent HMG-CoA reductase inhibitor targeting mevalonate pathway. (C) Heatmap summarizing drug synergy in 3D Ewing sarcoma cultures. Combinations of pitavastatin with the BCL-2 inhibitor ABT-199 (venetoclax), BCL-xL inhibitor A1155463, or MCL-1 inhibitor S63845 were additive in 2D cultures (NumScore = 0) but showed marked synergy in 3D spheroids across multiple concentration points. NumScore indicates the number of wells in the dose matrix where the observed effect exceeds Bliss-predicted additivity. (D) Heatmap of MaxScore values for the SK-N-MC cell line, comparing 3D and 2D cultures. Left: High MaxScores in 3D cultures indicate strong synergy across concentration points. Right: Low MaxScores in 2D cultures highlight reduced synergistic interaction. Orange boxes denote the IC₅₀ concentrations of both pitavastatin and A1155463.

    Journal: bioRxiv

    Article Title: Mevalonate pathway activation in Ewing sarcoma reveals a 3D-specific synergy between statins and BCL-xL inhibition

    doi: 10.1101/2025.11.20.689456

    Figure Lengend Snippet: (A) Schematic overview of the upper mevalonate pathway illustrating statin-mediated inhibition of HMG-CoA reductase. (B) Chemical structure of pitavastatin, a potent HMG-CoA reductase inhibitor targeting mevalonate pathway. (C) Heatmap summarizing drug synergy in 3D Ewing sarcoma cultures. Combinations of pitavastatin with the BCL-2 inhibitor ABT-199 (venetoclax), BCL-xL inhibitor A1155463, or MCL-1 inhibitor S63845 were additive in 2D cultures (NumScore = 0) but showed marked synergy in 3D spheroids across multiple concentration points. NumScore indicates the number of wells in the dose matrix where the observed effect exceeds Bliss-predicted additivity. (D) Heatmap of MaxScore values for the SK-N-MC cell line, comparing 3D and 2D cultures. Left: High MaxScores in 3D cultures indicate strong synergy across concentration points. Right: Low MaxScores in 2D cultures highlight reduced synergistic interaction. Orange boxes denote the IC₅₀ concentrations of both pitavastatin and A1155463.

    Article Snippet: S63845 and A-1155463 were obtained from Selleck Chemicals (Houston, TX, USA) and TargetMol (Boston, MA, USA).

    Techniques: Inhibition, Concentration Assay